IBB News and Press, iShares Biotechnology ETF From 05/05/23

2023-05-05 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-05-02 14:38:18 ET Summary Ascendis reported strong Q1 2023 Skytrofa revenue (EUR 31.6m) and 2023 guidance (EUR 150-160m), but the stock traded down likely due to the FDA's CRL on its PTH drug for manufacturing concerns. The FDA did not request additional clinical data, implyi...

2023-05-02 01:25:00 ET Summary Interest rates continue to drive markets, with central banks walking a fine line between taming inflation and avoiding recession. The Fed isn’t quite finished with the tightening cycle yet, even as the market remains optimistic that rates will...

2023-04-26 19:33:17 ET Summary We are reiterating the hold rating due to Igalmi launch uncertainties around market access and the limited commercial capacity of BTAI. Optimistic about upcoming Tranquility 2 and Serenity 3 trial readouts in 2Q23. Serenity 3 is considered fairly...

2023-04-25 16:37:49 ET Summary Positive Phase 2 ORCA-V1 trial results show cytisinicline's potential in helping users quit vaping, with an odds ratio of 2.6 compared to placebo, suggesting a strong case for FDA approval. Cytisinicline demonstrated a favorable safety profile with n...

2023-04-25 10:00:20 ET Summary Arbitration dismissal: Genmab's recent dismissal of its second arbitration case against Janssen regarding Darzalex Faspro royalties suggests that these royalties will likely cease after 2030. PDUFA date and pipeline focus: The market's attention shou...

2023-04-25 02:01:13 ET Summary To identify the most promising pharmaceutical companies with a market capitalization of more than $1 billion, we use an eight-step selection process, which will be discussed below. The following two articles will feature our list of the top 10 pharma...

2023-04-24 22:42:47 ET Summary Upgraded rating: TVTX's pegtibatinase shows promise for HCU treatment, especially with AGLE's disappointing competitor data. Positive pegtibatinase results: Dose-dependent tHcy reduction in COMPOSE study; favorable clinical threshold. Regulatory ...

2023-04-24 05:31:06 ET Summary Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. Biotech deal-making has been increasing, with large acquisitions such as Pfizer's acquisit...

2023-04-21 11:13:41 ET Summary We believe the M&A wave in the biotech sector presents a prime opportunity for investors to profit from the rising valuations of small and mid-cap firms in SPDR® S&P Biotech ETF. Big pharma companies, facing patent cliffs and pricing pre...